Evan Jones, Chairman and CEO
Mr. Jones is the Managing Member of jVen Capital, LLC, a life sciences investment company. Prior to forming jVen Capital, he was co-founder, Chairman and CEO of Digene Corporation, a publicly traded biotechnology company focused on women’s health and molecular diagnostic testing. He is a Board Member of Fluidigm, Inc., Foundation Medicine, Inc., and Veracyte, Inc. Mr. Jones is Vice-Chairman of the Board of the Children’s National Medical Center and a Board Member of the Children’s Research Institute. Mr. Jones is Chairman of the Board for the Campaign for Public Health, an organization dedicated to making public health and prevention a higher national priority. He serves on the Board of Directors of Research!America.
Mr. Jones received his BA degree from the University of Colorado and an MBA from The Wharton School, University of Pennsylvania.
Eric Winzer, CFO
Mr. Winzer joined OpGen as Chief Financial Officer in June 2009. Eric brings almost 30 years of experience in addressing diverse financial issues including raising capital, financial reporting, investor relations, banking, taxation, mergers and acquisitions, financial planning and analysis, and accounting operations. Eric is responsible for all financial functions at the Company.
Prior to joining Opgen, Eric served as Executive Vice President and Chief Financial Officer for Avalon Pharmaceuticals, Inc., a biotechnology company developing targeted therapeutics for oncology. Prior to Avalon, Eric was with Life Technologies Corporation (formerly Invitrogen Corporation), a provider of life science technologies for disease research and drug discovery, where he served as Senior VP and Chief Financial Officer, Executive Sponsor for Life’s ERP implementation, and as the VP of Finance. Previously held positions also include Eric’s tenure at Life Technologies Incorporated, where he assumed increasing responsibility as Chief Financial Officer, Secretary and Treasurer, and additionally held various financial positions at Genex Corporation. Currently, Eric serves as director and audit committee chair at Cytomedix, Inc.
Eric received his BA in Economics and Business Administration from McDaniel College and an MBA from Mount Saint Mary’s University.
Robert McG. Lilley, Chief Commercial Officer
Mr. Lilley was retained by OpGen in October 2014 as Chief Commercial Officer. Mr. Lilley is currently non‑executive Chairman of the Board of Directors of Immunexpress, Inc., a Seattle-based molecular diagnostic company focused on developing diagnostic tests for patients at risk of sepsis. He previously served as Senior Vice President, Global Sales and Marketing for Digene Corporation, from June 1999 until its sale to QIAGEN NV in 2007. He had held prior sales executive positions with Digene from March 1997 to June 1999. Mr. Lilley worked for QIAGEN NV as Senior Advisor, Molecular Diagnostics from August 2007 until September 2009. He previously served as Head of Europe, Middle East, and Africa (EMEA) Sales and Marketing for TDS Healthcare Information Systems, as well as Senior Vice President and General Manager EMEA of Alltel Healthcare Systems.
In 1970, Mr. Lilley joined the first Earth Day team, and he has retained an interest in environmental affairs since. Today he serves on the Boards of the Global Footprint Network, and Terra Global Capital, both based in the San Francisco Bay Area. He has also served on the Board of Trustees of The Center for Advanced Studies in the Behavioral Sciences (CASBS) at Stanford University. Mr. Lilley holds a BA from Yale University.
Vadim Sapiro, CIO
Mr. Sapiro joined OpGen in December, 2011 with responsibility for leading the development of the Company’s bioinformatics applications, software, databases and information technology operations. Prior to OpGen, Vadim was senior vice president at SAIC-Frederick overseeing the Information Systems Program for the National Cancer Institute at Frederick with responsibility for information technology, scientific computing and bioinformatics. Among Vadim’s projects were technical program management and operations for the cancer Biomedical Informatics Grid (caBIG™), the cancer Human Biobank (caHUB) and The Cancer Genome Atlas (TCGA). Prior to SAIC, Vadim was vice president for information technology with the J. Craig Venter Institute. Vadim is active in the regional and national technology and research communities, having served on many life sciences and biotech focused advisory boards and review committees.
Vadim holds a BS in Mathematics and Computer Science from the University of Maryland.
Terry Walker, PhD, Sr.VP, Research & Development
Dr. Walker’s responsibilities include leading the development of genomic technologies and new products supporting molecular diagnostics for infectious diseases. Prior to OpGen, Terry previously led drug target validation , biomarker discovery and clinical diagnostic development at Pfizer, GlaxoSmithKline (GSK), Becton Dickinson (BD), Duke University and The Biomarker Factory across most disease areas and stages of development from discovery through late clinical trials.
Terry received his PhD in Biophysical Chemistry from the University of Rochester with postdoctoral training in Biophysical Chemistry at the University of California, Berkeley.
David Hoekzema, VP, Business Development & Operations
Mr. Hoekzema joined OpGen in 2012 to expand technology and assay development partnerships in clinical diagnostics and life sciences. David is also responsible for OpGen’s production and service operations. He has over 25 years of experience in global biotechnology markets, with leadership and management roles spanning business development, sales and marketing, and commercial and technical operations at QIAGEN, Cambrex Biopharmaceuticals, Life Technologies, and Advanced Biotechnologies. Prior to OpGen, David was Vice President, Business Development at SAIC, leading the formation of technology partnerships for Frederick National Laboratory for Cancer Research.
David holds a BS in Biology from Frostburg State University and an MBA from the University of Maryland, Robert H. Smith School of Business.